Mon, 02 Jun 2025

Henry Hadad, Senior Vice President and Deputy General Counsel at Bristol-Myers Squibb, discusses how intellectual property (IP) protection is very much a natural right that encourages - not discourages - innovation, the incremental erosion of IP protections over the last 20 years, how the AI revolution is going to have a significant impact on the biopharmaceutical industry, and the need to restore and maintain the right balance between access and innovation to avoid slowing down biopharma’s robust innovation cycle.